Comparative analysis of postpartum depression incidence in patients with epilepsy on levetiracetam or lamotrigine monotherapy during pregnancy
Epilepsy & Behavior · 2025
DOI: 10.1016/j.yebeh.2025.110599 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Epilepsy & Behavior, 2025. Verfasst von Katelyn X Li und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology - Division of Epilepsy, Brigham and Women's Hospital, United States; Harvard Medical School, United States. Hauptthemen laut MEDLINE: Levetiracetam, Lamotrigine, Anticonvulsants, Epilepsy. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 31 Literaturangaben. Gefördert von: Epilepsy Foundation, Brigham and Women's Hospital BRI, Brigham and Women's Hospital.
Themen: Depression
Abstract (Originalsprache)
The objective of this study was to investigate differences in the rates of postpartum depression (PPD) among patients with epilepsy treated with either lamotrigine (LTG) or levetiracetam (LEV) monotherapy, two commonly prescribed anti-seizure medications (ASMs) during pregnancy, with differential effects on mood. This is an observational study of 84 pregnancies monitored at Brigham and Women's Hospital Epilepsy-Obstetrics clinics between January 2018 and June 2022. Clinical information on patient demographics, medical history, seizure types and frequency, and postpartum mood was collected. PPD was observed in 10 of the 84 pregnancies analyzed (11.9 %), as indicated by an Edinburgh Postnatal Depression Scale (EPDS) score ≥ 10 approximately six weeks post-delivery. We found that rates of PPD did not differ significantly by ASM (P = 1.0): 10.4 % of pregnancies managed with LTG monotherapy were associated with a PPD episode, as compared to 13.9 % of pregnancies managed with LEV monotherapy. Analysis suggested higher PPD risk with antidepressant use in pregnancy and non-white race, and a possible protective effect of breastfeeding and multiparity. In conclusion, we found no difference in PPD incidence between patients on LTG and LEV monotherapy, despite the ASMs' varied mood-related effects.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology - Division of Epilepsy, Brigham and Women's Hospital, United States; Harvard Medical School, United States.
- Department of Neurology - Division of Epilepsy, Brigham and Women's Hospital, United States; University of Massachusetts Medical School, United States.
- Harvard Medical School, United States; Department of Obstetrics and Gynecology - Division of Maternal-Fetal Medicine, Brigham and Women's Hospital, United States.
- University of Pittsburgh, United States.
- Department of Neurology - Division of Epilepsy, Brigham and Women's Hospital, United States; Harvard Medical School, United States; Division of Women's Health, Brigham & Women's Hospital, United States. Electronic addre…
Förderung
- Epilepsy Foundation
- Brigham and Women's Hospital BRI
- Brigham and Women's Hospital
Zitieren
APA
Li, K. X., Purandare, M., Lemley, R., McElrath, T. F., Shashkova, E., Pennell, P. B., Dworetzky, B. A., & Voinescu, P. E. (2025). Comparative analysis of postpartum depression incidence in patients with epilepsy on levetiracetam or lamotrigine monotherapy during pregnancy. Epilepsy & Behavior. https://doi.org/10.1016/j.yebeh.2025.110599
Vancouver
Li KX, Purandare M, Lemley R, McElrath TF, Shashkova E, Pennell PB, et al. Comparative analysis of postpartum depression incidence in patients with epilepsy on levetiracetam or lamotrigine monotherapy during pregnancy. Epilepsy & Behavior. 2025. doi:10.1016/j.yebeh.2025.110599
BibTeX
@article{Li2025,
author = {Li, Katelyn X and Purandare, Mallika and Lemley, Regan and McElrath, Thomas F and Shashkova, Elizabeth and Pennell, Page B and Dworetzky, Barbara A and Voinescu, P Emanuela},
title = {Comparative analysis of postpartum depression incidence in patients with epilepsy on levetiracetam or lamotrigine monotherapy during pregnancy},
journal = {Epilepsy & Behavior},
year = {2025},
doi = {10.1016/j.yebeh.2025.110599}
}
EUVIMED